Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...

Good news: cancer death rates in the UK have fallen to their lowest level on record. According to the latest statistics from Cancer Research UK, between 2022 and 2024, around 247 people per 100,000 ...

Pancreatic cancer is one of the most dangerous and difficult cancers to treat. Doctors often struggle to detect it early because the disease usually causes few symptoms in the beginning. By the time ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The ...

MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for ...

A new cohort study suggests that Medicaid expansion is associated with a lower mortality risk among patients with pancreatic ...

The projections show the growing impact of lifestyle-related risk factors and gaps in early detection—while pointing to clear steps people can take now to reduce their risk. “These rising cancer rates ...

Pancreatic cancer is one of the most dangerous forms of cancer in the world. Many patients do not know they have the disease ...

The federal government funds nearly 80% of all pancreatic cancer research. For pancreatic cancer — one of the deadliest ...

Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...

RASolute 302 Phase 3 catalyst, cash runway, and valuation risks for daraxonrasib. Read more macro analysis here.